Eli Lilly launched the 'Change the Course Commitment' aiming to treat as many diabetes and obesity patients in low- and middle-income countries (LMICs) as in high-income countries by 2040. Currently, only one in four patients in LMICs have access to Lilly's medicines compared to high-income countries. The initiative focuses on developing suitable medicines, registering them faster in LMICs, and strengthening health systems through partnerships. This follows Lilly's successful 30x30 initiative, which expanded healthcare access to 40 million people in resource-limited settings by 2025, five years ahead of schedule.
Eli Lilly And Co shares trade at USD 1,188.92 on Pluang as of Sep 28, 2026 17:41 WIB, up 0.44% for the day. The company holds a market cap of $1.05 trillion and an enterprise value of $1.10 trillion. This strong market presence supports its global health initiatives like the new Change the Course Commitment.
The FDA approved Eli Lilly's Onswik, a once-weekly basal insulin for adults with type 2 diabetes, marking a useful extension to its diabetes treatments. While the stock rose 2.85% to $1,183.76, this new insulin is unlikely to significantly change the...
The FDA has approved Olumiant (baricitinib), a once-daily pill, for treating severe alopecia areata (AA) in pediatric patients aged 12 and older. This approval is based on positive results from the BRAVE-AA-PEDS Phase 3 study, showing significant sca...
Novo Nordisk revealed a strategy to boost growth beyond its top obesity drugs Wegovy and Ozempic, facing patent expirations in the early 2030s. Despite promising a pipeline of new drugs, investors remain skeptical as Eli Lilly gains market share, esp...
The US FDA has approved Eli Lilly's once-weekly basal insulin, Onswik, for adults with type 2 diabetes, offering a new alternative to daily insulin injections. Onswik, used alongside diet and exercise, can reduce injection frequency by over 300 times...
Eli Lilly reported a 47.7% revenue increase in Q2 2026, driven by strong sales of Mounjaro and Zepbound, and raised its full-year revenue guidance. Pfizer showed modest growth with a 5.4% revenue increase in Q1 2026, focusing on oncology and obesity ...
